Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$3.11
+1.0%
$2.97
$2.30
$5.54
$184.44M-0.16314,420 shs307,537 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$7.65
-3.0%
$6.58
$4.09
$17.24
$168.66M0.84282,928 shs100,908 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$13.59
-0.9%
$12.59
$5.22
$27.38
$172.71M0.43154,763 shs133,040 shs
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$0.77
-7.4%
$0.99
$0.69
$4.99
$39.92M1.63329,629 shs257,791 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
+3.49%+14.76%+0.97%+14.76%+24.90%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-3.04%+1.19%+2.41%+71.52%-42.87%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+8.50%+3.90%+8.55%-1.95%+128.40%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-7.54%-2.50%-32.28%-15.20%-79.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
2.5332 of 5 stars
3.54.00.00.00.01.70.0
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
3.6139 of 5 stars
3.42.00.04.70.02.50.0
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.2803 of 5 stars
3.50.01.72.73.32.51.3
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
2.8386 of 5 stars
3.44.00.00.00.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
3.00
Buy$9.00189.39% Upside
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.80
Moderate Buy$18.00135.29% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50124.43% Upside
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
2.83
Moderate Buy$7.50871.50% Upside

Current Analyst Ratings Breakdown

Latest STTK, ELDN, ENTA, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$9.00
6/3/2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/A$1.98 per shareN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$67.64M2.42N/AN/A$6.08 per share1.26
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.85$0.87 per share15.56$2.05 per share6.63
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$5.72M6.46N/AN/A$1.67 per share0.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$36.18M-$2.10N/AN/AN/AN/A-79.54%-41.62%8/18/2025 (Estimated)
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6919.70N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$75.41M-$1.39N/AN/AN/AN/A-79.69%-69.13%7/30/2025 (Estimated)

Latest STTK, ELDN, ENTA, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q3 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.10N/AN/AN/A$16.21 millionN/A
5/14/2025Q1 2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$0.28-$0.08+$0.20-$0.08N/AN/A
5/12/2025Q2 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
5/1/2025Q1 2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.29-$0.27+$0.02-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.32%N/A26.09%3 Years
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/AN/AN/AN/AN/A

Latest STTK, ELDN, ENTA, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/A
13.90
13.91
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
5.29
5.29
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/A
9.08
9.08

Institutional Ownership

CompanyInstitutional Ownership
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
56.77%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
58.74%

Insider Ownership

CompanyInsider Ownership
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
12.30%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
13.89%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
12.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
1059.88 million52.52 millionOptionable
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
16021.38 million18.41 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10047.90 million42.15 millionOptionable

Recent News About These Companies

Shattuck Labs, Inc. (STTK) - Yahoo Finance
Shattuck Labs Full Year 2024 Earnings: Misses Expectations
Shattuck Labs reports Q4 EPS (37c), consensus (32c)
H.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)
Shattuck Labs initiated with an Outperform at Leerink
H.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)
Shattuck Labs’ SL-325 shows positive results in inflammatory bowel disease

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eledon Pharmaceuticals stock logo

Eledon Pharmaceuticals NASDAQ:ELDN

$3.11 +0.03 (+0.97%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$3.26 +0.15 (+4.69%)
As of 07/7/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$7.65 -0.24 (-3.04%)
As of 07/7/2025 04:00 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$13.59 -0.13 (-0.95%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$13.57 -0.02 (-0.15%)
As of 07/7/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Shattuck Labs stock logo

Shattuck Labs NASDAQ:STTK

$0.77 -0.06 (-7.37%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$0.78 +0.01 (+0.65%)
As of 07/7/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.